[{"orgOrder":0,"company":"AI VIVO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"AI VIVO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AI VIVO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AI VIVO \/ Undisclosed"},{"orgOrder":0,"company":"Exvastat","sponsor":"Innovative Medicines Initiative","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Imatinib Mesylate","moa":"PTK","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Exvastat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Exvastat \/ Innovative Medicines Initiative","highestDevelopmentStatusID":"1","companyTruncated":"Exvastat \/ Innovative Medicines Initiative"},{"orgOrder":0,"company":"YD Life Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"YD Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"YD Life Science \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"YD Life Science \/ Not Applicable"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Aerami","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Imatinib Mesylate","moa":"PTK","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Vectura Ltd \/ Aerami","highestDevelopmentStatusID":"5","companyTruncated":"Vectura Ltd \/ Aerami"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"RA Capital Incubator","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.070000000000000007,"dosageForm":"Inhalation","sponsorNew":"Aerovate Therapeutics \/ RA Capital Incubator","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ RA Capital Incubator"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Hangzhou Chance Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Imatinib Mesylate","moa":"PDGFRB","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerami Therapeutics \/ Hangzhou Chance Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Hangzhou Chance Pharmaceuticals"},{"orgOrder":0,"company":"PH Precision Med","sponsor":"Tenax Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Imatinib Mesylate","moa":"PDGFRB","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"PH Precision Med","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"oral","sponsorNew":"PH Precision Med \/ Tenax Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PH Precision Med \/ Tenax Therapeutics"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"FoxWayne Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"Imatinib Mesylate","moa":"ABL1 gene","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Aerami Therapeutics \/ FoxWayne Enterprises","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ FoxWayne Enterprises"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"ABL1 gene","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder For Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGFRB","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"Tenax Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Imatinib Mesylate","moa":"PDGF","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Enteric Capsule","sponsorNew":"Tenax Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dry Powder Inhalation","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tenax Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tenax Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.02,"dosageForm":"Enteric Capsule","sponsorNew":"Tenax Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tenax Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerami Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aerami Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution for Nebulizer","sponsorNew":"Aerami Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aerami Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Dry Powder","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aerovate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Imatinib Mesylate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Aerovate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aerovate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Aerovate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kura Oncology \/ Not Applicable"},{"orgOrder":0,"company":"Kura Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ziftomenib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Kura Oncology","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Kura Oncology \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Kura Oncology \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Imatinib (mesylate)

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Details : Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 08, 2020

                          Lead Product(s) : Imatinib Mesylate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Aerami

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Skyepharma Company Banner

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 24, 2024

                          Lead Product(s) : Ziftomenib,Imatinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.

                          Brand Name : KO-539

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 08, 2024

                          Lead Product(s) : Ziftomenib,Imatinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AV-101 (imatinib) is a novel dry powder inhaled formulation which inhibits the BCR-ABL tyrosine kinase. It is being evaluated for the treatment of pulmonary arterial hypertension.

                          Brand Name : AV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 17, 2024

                          Lead Product(s) : Imatinib Mesylate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AV-101 (imatinib) is a novel dry powder inhaled formulation which is being evaluated for the treatment of pulmonary arterial hypertension. It is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase.

                          Brand Name : AV-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 20, 2023

                          Lead Product(s) : Imatinib Mesylate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.

                          Brand Name : AER-901

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 24, 2023

                          Lead Product(s) : Imatinib Mesylate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.

                          Brand Name : AER-901

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 03, 2023

                          Lead Product(s) : Imatinib Mesylate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.

                          Brand Name : AER-901

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 23, 2023

                          Lead Product(s) : Imatinib Mesylate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The Company intends to use the net proceeds to progress the clinical development of TNX-201 (imatinib) for the treatment of PAH and levosimendan for the treatment of PH-HFpEF, toward regulatory approval for the treatment of these and potentially other in...

                          Brand Name : TNX-201

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 03, 2023

                          Lead Product(s) : Imatinib Mesylate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Roth Capital Partners

                          Deal Size : $15.6 million

                          Deal Type : Public Offering

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : AER-901 is a drug-device combination that is designed to deliver potentially reverse-remodeling therapy with imatinib mesylate deeply and efficiently throughout the diseased tissue of the lung via the FOX® nebulizer.

                          Brand Name : AER-901

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 21, 2022

                          Lead Product(s) : Imatinib Mesylate

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank